No Result

View All Result

No products in the cart.

Home Tag myeloma

Tag: myeloma

Chemotherapy and stem-cell transplant for multiple myeloma remain superior

CAR+ T-cell lymphoma linked to cilta-cel therapy in myeloma

byZhenyu Liand1 others

March 7, 2025

1. This study describes two cases of malignant monoclonal T-cell lymphoproliferation following ciltacabtagene autoleucel (cilta-cel) Chimeric Antigen Receptor T-cell (CAR ...

#VisualAbstract: Belantamab Mafodotin, Pomalidomide, and Dexamethasone Improve Outcomes in Multiple Myeloma

byAstrid Bradshawand1 others

June 13, 2024

#VisualAbstract: Addition of itacitinib to corticosteroids did not show clinical benefit over placebo in initial treatment of acute graft-versus-host disease

byKathleen Lau

January 6, 2022

#VisualAbstract In a Netherlands cohort, early mortality decreased in patients with multiple myeloma from 1999 onwards

byKathleen Lau

November 19, 2021

$#VisualAbstract Indatuximab ravtansine in combination with immunomodulatory drugs shows objective and clinical response in patients with relapsed or refractory multiple myeloma$

#VisualAbstract Indatuximab ravtansine in combination with immunomodulatory drugs shows objective and clinical response in patients with relapsed or refractory multiple myeloma

byKathleen Lau

September 23, 2021

#VisualAbstract Reduced-dose lenalidomide regimen significantly prolongs event-free survival in elderly, intermediate-fit patients with newly diagnosed multiple myeloma

byKathleen Lau

June 11, 2021

#VisualAbstract TOURMALINE-MM2 trial: Oral ixazomib, lenalidomide, and dexamethasone is a feasible and well-tolerated all-oral regimen in non-transplant, newly diagnosed multiple myeloma

byKathleen Lau

April 1, 2021

$#VisualAbstract Dexamethasone improved isatuximab efficacy in patients with relapsed/refractory multiple myeloma$

#VisualAbstract Dexamethasone improved isatuximab efficacy in patients with relapsed/refractory multiple myeloma

byKathleen Lau

March 26, 2021

#VisualAbstract CARDAMON case series: Thrombotic microangiopathy in newly diagnosed multiple myeloma patients receiving carfilzomib, cyclophosphamide, and dexamethasone can be preventatively managed

byKathleen Lau

March 12, 2021

$#VisualAbstract CASTOR trial follow-up: Health-related quality of life was maintained in patients treated with daratumumab, bortezomib, and dexamethasone over time for relapsed or refractory multiple myeloma$

#VisualAbstract CASTOR trial follow-up: Health-related quality of life was maintained in patients treated with daratumumab, bortezomib, and dexamethasone over time for relapsed or refractory multiple myeloma

byKathleen Lau

March 4, 2021

Page 1 of 3 1 2 3 Next

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

No Result

View All Result